DADC
PRQR icon

D.A. Davidson & Co’s ProQR Therapeutics PRQR Stock Holding History

D.A. Davidson & Co’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,772
Closed -$126K – 1321
2021
Q4 		$126K Buy
+15,772
New +$120K ﹤0.01% 1230

Other funds holding PRQR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.A. Davidson & Co's PRQR Position: Q1 2022 in Review

D.A. Davidson & Co sold out of ProQR Therapeutics (PRQR) in Q1 2022, closing a stake of 15,772 shares — an estimated $126K sold.

D.A. Davidson & Co first reported a position in PRQR in Q4 2021 and held it in 1 quarter. The position peaked at $126K in Q4 2021. 58 funds tracked by Wall St. Rank hold PRQR as of Q1 2022.

  • D.A. Davidson & Co reported no remaining ProQR Therapeutics position as of Q1 2022 after selling out during the quarter.
  • D.A. Davidson & Co sold 15,772 ProQR Therapeutics shares in Q1 2022, an estimated $126K.
  • D.A. Davidson & Co first reported a position in ProQR Therapeutics in Q4 2021 and held it in 1 quarter.
  • D.A. Davidson & Co's ProQR Therapeutics position peaked at $126K in Q4 2021.
  • 58 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2022.

Based on D.A. Davidson & Co's 13F filing for Q1 2022, filed 12 May 2022.